Both, chronic kidney disease (CKD) and dialysis itself can lead to cardiovascular alterations such as atherosclerosis and left ventricular hypertrophy (LVH). Even though the quality and efficacy of haemodialysis therapy have greatly improved in recent years, cardio-vascular disease (CVD) remains the leading cause of death in haemodialysis patients. Fresenius Medical Care?s mission is to enable nephrologists to provide the best possible therapy for their long-term haemodialysis patients, in order to minimise the risk of CVD. We strive to continuously refine and develop new dialysis therapies and products to improve the clinical outcomes of dialysis patients. We set the standards for both convective therapies and standard haemodialysis as we are fully aware of our responsibility to provide high quality treatment no matter if HDF or HD.